ICOS blockade breaks Treg immune suppression in triple-negative breast cancer models
Start here
Researchers report that blocking ICOS disrupts the regulatory T cell immunosuppressive niche in the tumor microenvironment of triple-negative breast cancer. In syngeneic orthotopic mouse models, ICOS blockade restrained primary tumor growth, reduced spontaneous metastasis and prolonged survival. The findings, posted as a preprint in bioRxiv Cancer Biology on October 23, 2026, position ICOS as a candidate target for overcoming immune suppression in a breast cancer subtype with limited treatment options. The work is preclinical; questions still open include how the approach translates to human tumors, which combinations it should be tested with, and whether the benefits extend beyond the models studied.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- biorxiv.orgICOS blockade alleviates immune suppression in breast tumor microenvironment
Researchers found that ICOS blockade disrupts the Treg immunosuppressive niche in triple-negative breast cancer, and in syngeneic orthotopic models restricts primary tumor growth, reduces spontaneous metastasis and prolongs survival.
Heat trend for this story
Heat now 7·Peak in the comparable set 10 (Oct 23 08:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.